CNB-001 reduced BW gain, adiposity, heart weight, liver weight, serum TGs and IL-6 levels. CNB-001 increased energy expenditure, reduced fasting glucose concentrations, improved glucose tolerance and insulin sensitivity, and increased ex vivo gastrocnemius muscle glucose uptake. CNB-001 attenuated hepatic steatosis by decreasing lipid accumulation and hepatic TG content. CNB-001 restored insulin signaling via upregulation of p-AKT and p-IR expression, reduced ER stress via decreased p-eIF2α and GRP78 expression, and decreased PTP1B expression in gastrocnemius muscles. Here, EIF2A is linked to fatty liver disease.